significantly lower – Page 11 – Communicable Diseases Research

Seven Months after Mild COVID-19: A Single-Centre Controlled Follow-Up Study in the District of Constance (FSC19-KN)

Clinical Trial

Published on 2022-08-122022-10-04
Journal: International journal of clinical practice [Category] SARS, 임상,

Immunogenicity and immune-persistence of the CoronaVac or Covilo inactivated COVID-19 Vaccine: a 6-month population-based cohort study

Article

Published on 2022-08-122022-11-15
Journal: Frontiers in Immunology [Category] SARS, 변종, 진단, 치료기술,

[키워드] acute respiratory syndrome anti-SARS-CoV-2 antibody antibody Characteristics chronic respiratory disease CoronaVac coronavirus coronavirus disease COVID-19 COVID-19 vaccine COVID-19 vaccines delta variant detectable disease Dynamic changes Effectiveness elicited Emergency use IgM response immunogenicity Immunoglobulin inactivated Inactivated vaccine investigated live SARS-CoV-2 neutralizing antibody nucleocapsid Older age pandemic persistence population-based cohort Protective Protein pseudovirus recipient responses SARS-CoV-2 SARS-CoV-2 variants SARS-CoV-2-specific antibodies seroconversion rates seroconverted significantly lower the SARS-CoV-2 vaccination Vaccine vaccine dose wildtype
[DOI] 10.3389/fimmu.2022.939311 PMC 바로가기

Vaccine effectiveness of two-dose BNT162b2 against symptomatic and severe COVID-19 among adolescents in Brazil and Scotland over time: a test-negative case-control study

Research article

Published on 2022-08-092022-10-05
Journal: The Lancet. Infectious Diseases [Category] SARS, 변종,

[키워드] 95% CI Abstract adjusted odds ratio analysed Antigen association B.1.1.529 BNT162b2 booster dose Brazil case-control study collected Control Council country COVID-19 COVID-19 infection COVID-19-related symptom death dose Effectiveness excluded Fazer finding funding hospitalisation individual information Innovation material Medical Research Council National negative test Occurrence of BNT162b2 outcome peaked Positive test receiving recorded reducing remained SARS-CoV-2 SARS-CoV-2 RT-PCR SARS-CoV-2 test Scottish second dose severe COVID-19 severe disease Sex significantly lower symptom onset symptomatic symptomatic infection symptomatic SARS-CoV-2 infection Symptoms the SARS-CoV-2 translation vaccination Vaccine vaccine efficacy variant Wellcome Trust
[DOI] 10.1016/S1473-3099(22)00451-0 [Article Type] Research article

Evaluation of serological response to anti-SARS-CoV-2 mRNA vaccination in hematological patients

혈액학적 환자에서 anti-SARS-CoV-2 mRNA 백신접종에 대한 혈청학적 반응 평가

Article

Published on 2022-08-082022-09-12
Journal: Frontiers in Immunology [Category] SARS, 진단,

[키워드] Administered anti-SARS-CoV-2 anti-SARS-CoV-2 IgG anti-SARS-CoV-2 vaccination Anti-spike anti-Spike IgG anti-spike IgG level antibody Antibody titer association Cell Cohort cohort of patient Concentration control arm control group Cutoff demographic variable difference drug Effect evaluated greater health worker healthy healthy subjects hematological Hematological malignancies Hematological malignancy heterogeneous highest identify IgG IgG titer immune system immunoassay Immunocompromised patients Immunosuppression implication inhibitor Italy leukemia Microparticle molecular mRNA mRNA vaccination mRNA vaccine onco-hematology. parameter pathology Patient patients performed Predictive reached reduced reported SARS-CoV-2 SARS-CoV-2 antibody second dose seroconversion rate serological response shown significantly lower spike IgG statistical significance steroid stratified Surveillance the mean the patient Therapies therapy treated tyrosine underlying disease vaccination Vaccine was reduced
[DOI] 10.3389/fimmu.2022.892331 PMC 바로가기 [Article Type] Article

Efficacy and safety of anakinra in adults presenting deteriorating respiratory symptoms from COVID-19: A randomized controlled trial

Randomized Controlled Trial

Published on 2022-08-042022-10-04
Journal: PLoS ONE [Category] SARS, 임상,

Systemic autoimmune myopathies: a prospective phase 4 controlled trial of an inactivated virus vaccine against SARS-CoV-2

전신 자가면역 근병증: SARS-CoV-2에 대한 비활성화된 바이러스 백신의 전향적 4상 대조 시험

Clinical Trial

Published on 2022-08-032022-09-12
Journal: Rheumatology (Oxford, England) [Category] SARS, 임상, 진단,

[키워드] 95%CI adverse event age All participant anti-SARS-CoV-2 anti-SARS-CoV-2 vaccine Autoimmune baseline Comorbidity comparable control group Controlled trial CoronaVac COVID-19 CTRL disease disease status dose drug evaluate Frequency geometric mean titre GMT HIV/AIDS IgG immune response immunogenicity immunogenicity analysis Immunosuppression in both group inactivated interquartile range IQR less median Mild moderate Myopathy myositis Neutralizing Neutralizing activity Neutralizing antibodies neutralizing antibody parameters participant Patient positive pre-vaccination protocol reduced RT-PCR S1/S2 Safe Safety SAM SARS-CoV-2 SARS-CoV-2 vaccine second dose Seroconversion serology Sex significantly lower systemic therapy Type Vaccine vaccine dose virus were excluded
[DOI] 10.1093/rheumatology/keab773 PMC 바로가기 [Article Type] Clinical Trial

Effects of cardiopulmonary bypass on immunoglobulin G antibody titres after SARS-CoV2 vaccination

Observational Study

Published on 2022-08-032022-10-05
Journal: Interactive cardiovascular and thoracic surgery [Category] SARS, 임상, 진단,

The Clinical Efficacy and Safety of Anti-Viral Agents for Non-Hospitalized Patients with COVID-19: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials

COVID-19를 가진 비 병원 환자에 대한 항 바이러스 제제의 임상 효능 및 안전성 : 무작위 대조 시험의 체계적인 검토 및 네트워크 메타 분석

Review

Published on 2022-08-022022-08-31
Journal: Viruses [Category] meta-analysis, 임상, 치료제,

[키워드] adverse event adverse events agent anti-viral agent anti-viral agents Anti-viral treatment best calculated clinical Clinical efficacy clinical setting Cochrane Library Controlled controlled trials COVID-19 death determined by Disease progression followed by Hospitalization increased risk Intravenous remdesivir investigated lowest molnupiravir network Network meta-analysis Nirmatrelvir nirmatrelvir plus ritonavir Patient patients with COVID-19 Placebo Probability Randomized controlled trial RCT RCTs receiving registry Remdesivir review risk risk of COVID-19 Ritonavir Safety searched shown significantly lower the WHO tolerable Treatment Web of Science WHO International Clinical Trials Registry Platform
[DOI] 10.3390/v14081706 PMC 바로가기 [Article Type] Review

Antibody evolution to SARS-CoV-2 after single-dose Ad26.COV2.S vaccine in humans

인간에서 단회 투여 Ad26.COV2.S 백신 후 SARS-CoV-2로의 항체 진화

Article

Published on 2022-08-012022-09-11
Journal: The Journal of Experimental Medicine [Category] COVID19(2023년), MERS, SARS, 변종, 진단,

Therapeutic anticoagulation using heparin in early phase severe coronavirus disease 2019: A retrospective study

Observational Study

Published on 2022-08-012022-10-05
Journal: The American journal of emergency medicine [Category] 임상,

[키워드] administration adverse event Anticoagulant anticoagulation association Care Characteristics Coronavirus disease 2019 COVID-19 Critical care disease early administration early phase ECMO Effect extracorporeal membrane oxygenation group groups heparin hospital ICU in-hospital mortality in-hospital mortality rate intensive care intensive care unit Japan mechanical ventilation multivariate model outcome Oxygen therapy Patient Pneumonia retrospective Retrospective study secondary outcome severe coronavirus disease severe COVID-19 patient Severe COVID-19 pneumonia significantly significantly lower systemic anticoagulation therapeutic therapeutic anticoagulation therapy unfractionated heparin ventilator-free day VFD
[DOI] 10.1016/j.ajem.2022.05.031 PMC 바로가기 [Article Type] Observational Study